Displaying 41 - 60 of 336
Amgen, Inc. and Horizon Therapeutics plc, In the Matter of
In August 2023, the FTC reached a proposed consent order with Amgen Inc. to address the potential competitive harm that would result from Amgen’s $27.8 billion acquisition of Horizon Therapeutics plc. As part of a nationwide settlement of their challenge to the acquisition, the FTC and attorneys general from six states – California, Illinois, Minnesota, New York, Washington, and Wisconsin – also dismissed the related federal court preliminary injunction action, allowing the transaction to proceed, with the conditions imposed by the order. In December 2023, the FTC finalized the consent order with Amgen Inc. and appointed a monitor.
Statement Regarding the Termination of Sanofi’s Proposed Acquisition of Maze Therapeutics’ Pompe Disease Drug
FTC Seeks to Block Sanofi’s Acquisition of Rare Disease Drug that Threatens Sanofi’s Monopoly
Mylan Pharmaceuticals, et al. v. Sanofi-Aventis, et al.
FTC Files Amicus Brief Outlining Anticompetitive Harm Caused by Improper Orange Book Listings
FTC Challenges More Than 100 Patents as Improperly Listed in the FDA’s Orange Book
FTC Staff Comment to Department of Labor on Proposed Amendments to Regulations Implementing the Mental Health Parity and Addiction Equity Act
FTC Issues Policy Statement on Brand Pharmaceutical Manufacturers’ Improper Listing of Patents in the Food and Drug Administration’s ‘Orange Book’
Federal Trade Commission Statement Concerning Brand Drug Manufacturers' Improper Listing of Patents in the Orange Book
Amgen Inc. and Horizon Therapeutics plc; Analysis of Agreement Containing Consent Order To Aid Public Comment
FTC Reaches Proposed Settlement with Surescripts in Illegal Monopolization Case
Statement of Chair Lina M. Khan Regarding the Policy Statement Concerning Reliance on Prior PBM-Related Advocacy Statements and Reports
FTC Votes to Issue Statement Withdrawing Prior Pharmacy Benefit Manager Advocacy
FTC Announces Tentative Agenda for July 20 Open Commission Meeting
FTC Files Amicus Brief in Bystolic Antitrust Litigation Supporting Competition in the Hypertension Drug Market
FTC Further Expands Inquiry Into Prescription Drug Middlemen Industry Practices
FTC, DOJ Issue Summary on Joint Pharmaceutical Merger Analysis Workshop
Displaying 41 - 60 of 336